2. Dose intensity data for adjuvant studies.

Study	Term used to represent dose intensity	Taxane followed by anthracycline	Anthracycline followed by taxane
Abe 2013	Mean relative dose intensitya	Docetaxel: 95.2% FEC: 98.9%	Docetaxel: 94.2% FEC: 97.8%
AERO B03 2007	Median relative dose intensity	Docetaxel: 96% (range: 25–104) Epirubicin: 96% (range: 0–102) Cyclophosphamide: 95% (range: 0–102)	Docetaxel: 81% (range: 0–102) Epirubicin: 97% (range: 66–102) Cyclophosphamide: 97% (range: 61–102)
Puhalla 2008	Mean relative dose intensity	Docetaxel: 96% Doxorubicin: 95%	Docetaxel: 82% Doxorubicin: 96%
Wildiers 2009a	Mean dose intensityb	Docetaxel: 99% FEC: 97%	Docetaxel: 97% FEC: 97%
Wildiers 2009b (dose‐dense)	Mean dose intensityb	Docetaxel: 111% FEC: 143%	Docetaxel: 108% FEC: 146%

FEC: fluorouracil, epirubicin, cyclophosphamide.

^aData used based on the reporting of findings in the abstract and Table 2 in the trial publication. The docetaxel and FEC percentages were switched in the text in the Results section. Therefore, the consistency of results presented in Table 2 and abstract were considered to be the most accurate reflection of the results.

^bDefined as the dose intensity achieved in intervention or comparator arm for a participant who received all intended doses with no cycle delay or dose reduction.